Astrazeneca Plc (AZN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2014 | 12-2013 | 12-2012 | 12-2011 | 12-2010 | |
| Sales | 26,095,000 | 25,711,000 | 27,973,000 | 33,591,000 | 33,269,000 |
| Cost of Goods | 5,842,000 | 5,261,000 | 5,393,000 | 6,026,000 | 6,389,000 |
| Gross Profit | 20,253,000 | 20,450,000 | 22,580,000 | 27,565,000 | 26,880,000 |
| Operating Expenses | 18,148,000 | 16,771,000 | 14,695,000 | 17,030,000 | 16,098,000 |
| Operating Income | 2,105,000 | 3,679,000 | 7,885,000 | 10,535,000 | 10,782,000 |
| Interest Expense | 963,000 | 492,000 | 933,000 | 980,000 | 1,022,000 |
| Other Income | 104,000 | 80,000 | 766,000 | 2,812,000 | 1,217,000 |
| Pre-tax Income | 1,246,000 | 3,267,000 | 7,718,000 | 12,367,000 | 10,977,000 |
| Income Tax | 11,000 | 696,000 | 1,391,000 | 2,351,000 | 2,896,000 |
| Net Income Continuous | 1,235,000 | 2,571,000 | 6,327,000 | 10,016,000 | 8,081,000 |
| Minority Interests | -2,000 | -15,000 | -30,000 | -33,000 | -28,000 |
| Net Income | $1,233,000 | $2,556,000 | $6,297,000 | $9,983,000 | $8,053,000 |
| EPS Basic Total Ops | 0.98 | 2.04 | 4.99 | 7.33 | 5.60 |
| EPS Basic Continuous Ops | 0.98 | 2.04 | 4.99 | 7.33 | 5.60 |
| EPS Diluted Total Ops | 0.98 | 2.04 | 4.98 | 7.30 | 5.57 |
| EPS Diluted Continuous Ops | 0.98 | 2.04 | 4.98 | 7.30 | 5.57 |
| EBITDA(a) | $5,491,000 | $8,342,000 | $11,169,000 | $15,897,000 | $14,740,000 |